Exact Mass: 559.1254084

Exact Mass Matches: 559.1254084

Found 34 metabolites which its exact mass value is equals to given mass value 559.1254084, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

dTDP-D-desosamine

dTDP-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-D-glucose; dTDP-alpha-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucose; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucopyranose

C18H31N3O13P2 (559.1332056)

dTDP-L-megosamine

C18H31N3O13P2 (559.1332056)

dTDP-beta-L-evernosamine

dTDP-beta-L-evernosamine; dTDP-3-amino-2,3,6-trideoxy-3-C-methyl-4-O-methyl-beta-L-arabino-hexopyranose

C18H31N3O13P2 (559.1332056)

Gadoteridol

3-methyl-16,19,24-trioxo-2,17,18,25-tetraoxa-5lambda5,8lambda5,11lambda5,14lambda5-tetraaza-1-gadolinaoctacyclo[9.6.3.3^{1,8}.2^{5,14}.0^{1,5}.0^{1,8}.0^{1,11}.0^{1,14}]pentacosan-2-ium-5,8,11,14-tetrakis(ylium)-1,1-diuide

C17H29GdN4O7 (559.1277253999999)

Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

Acetic acid, 2-(4-((5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol-1-yl)sulfonyl)phenoxy)-

C25H25N3O8S2 (559.108301)

C20H33NO17

C20H33NO17 (559.1748408000001)

Tetra-Ac-Antibiotic A 33853

C28H21N3O10 (559.1226886000001)

convolutamide A|N-Tetradecanoyl-Deacylconvolutamide

C24H35Br2NO4 (559.0932670000001)

leporizine B

C25H25N3O8S2 (559.108301)

Gadoteridol

gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate

C17H29GdN4O7 (559.1277253999999)

V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

4-(4-METHYLTHIOPHEN-2-YL)-N-(4-(MORPHOLINOMETHYL)PHENYL)-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE

C29H29N5O3S2 (559.1711724)

Bis[1-(2-pyridylazo)-2-naphtholato]copper(II)

C30H20CuN6O2 (559.094365)

aluminum phthalocyanine hydroxide

C32H20AlN8O (559.15754)

GADOTERIC ACID

[2,2,2,2-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-kappa(4)N(1),N(4),N(7),N(10))tetraacetato(3-)]gadolinium

C16H25GdN4O8 (559.091342)

V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media D064449 - Sequestering Agents > D002614 - Chelating Agents

2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex

C28H37ClNPPd (559.1386752000001)

7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (-)-mandelate

C24H23F6N5O4 (559.165415)

BAY 1161909

C29H26FN5O4S (559.1689448000001)

4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside

C24H24F3NO11 (559.130139)

Galicaftor

C28H21F4NO7 (559.1254084)

C87006 - Pharmacological Chaperone

dTDP-alpha-D-desosamine

C18H31N3O13P2 (559.1332056)

Biotinol-5-AMP

C20H30N7O8PS (559.161411)

[6-(Diethylamino)-9-(2,4-disulfophenyl)xanthen-3-ylidene]-diethylazanium

C27H31N2O7S2+ (559.1572596)

Gadolinium-HP-Do 3A

C17H29GdN4O7 (559.1277253999999)

V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide

C24H25F4N3O6S (559.1400118)

Apalcillin potassium

C25H22KN5O6S (559.0927812)

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(6,7-dimethoxy-2H-1,3-benzodioxol-5-yl)-2-hydroxy-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C22H29N3O12S (559.1471874000001)

(3s)-3-(3,4-dibromo-5-hydroxyphenyl)-3-hydroxy-1-tetradecanoylpyrrolidin-2-one

C24H35Br2NO4 (559.0932670000001)

12,13,25,26-tetrahydroxy-8,9,9-trimethyl-7-oxa-27,28-dithia-3,16,18-triazaoctacyclo[12.12.2.0¹,¹⁶.0³,¹⁴.0⁴,¹².0⁶,¹⁰.0¹⁷,²⁵.0¹⁹,²⁴]octacosa-6(10),19,21,23-tetraene-2,11,15-trione

12,13,25,26-tetrahydroxy-8,9,9-trimethyl-7-oxa-27,28-dithia-3,16,18-triazaoctacyclo[12.12.2.0¹,¹⁶.0³,¹⁴.0⁴,¹².0⁶,¹⁰.0¹⁷,²⁵.0¹⁹,²⁴]octacosa-6(10),19,21,23-tetraene-2,11,15-trione

C25H25N3O8S2 (559.108301)

(1s,8r,13s,14s,17s,26s)-12,13,25,26-tetrahydroxy-8,9,9-trimethyl-7-oxa-27,28-dithia-3,16,18-triazaoctacyclo[12.12.2.0¹,¹⁶.0³,¹⁴.0⁴,¹².0⁶,¹⁰.0¹⁷,²⁵.0¹⁹,²⁴]octacosa-6(10),19,21,23-tetraene-2,11,15-trione

(1s,8r,13s,14s,17s,26s)-12,13,25,26-tetrahydroxy-8,9,9-trimethyl-7-oxa-27,28-dithia-3,16,18-triazaoctacyclo[12.12.2.0¹,¹⁶.0³,¹⁴.0⁴,¹².0⁶,¹⁰.0¹⁷,²⁵.0¹⁹,²⁴]octacosa-6(10),19,21,23-tetraene-2,11,15-trione

C25H25N3O8S2 (559.108301)

3-(3,4-dibromo-5-hydroxyphenyl)-3-hydroxy-1-tetradecanoylpyrrolidin-2-one

C24H35Br2NO4 (559.0932670000001)

[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-{[(2r,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy}oxan-2-yl]methyl 3-hydroxy-7-methoxy-2-methylidene-1,4-benzoxazine-5-carboxylate

C23H29NO15 (559.1537124)